Takeda shutting US vaccine R&D sites in global restructure

By Dan Stanton contact

- Last updated on GMT

Dengue fever is one of the vaccines in Takeda's pipeline
Dengue fever is one of the vaccines in Takeda's pipeline

Related tags: Influenza, Clinical trial

Takeda is closing three US R&D facilities and relocating its global HQ to a site in Massachusetts as part of plans to consolidate its vaccine business.

This week Takeda has announced it is reshaping its Vaccine Business Unit (VBU) operations, establishing both global and regional hubs in order to support its norovirus, dengue and seasonal influenza pipeline.

The Japan-headquartered biopharma firm initiated steps to consolidate its global R&D and manufacturing  networks back in 2013​, in order to increase efficiency and save ¥120bn ($1bn) in operational costs by 2017, and as part of this latest shake-up it is shuttering several US vaccine sites.

Over the next two years, a site in Bozeman, Montana - acquired when Takeda bought LigoCyte Pharmaceuticals in 2012​ - will close, along with the former- Inviragen​ sites in Madison, Wisconsin and Fort Collins, Colorado, while the current VBU headquarters in Deerfield, Illinois, will be relocated to a new hub in the Boston/Cambridge, Massachusetts area.

“Our sites in Bozeman, Fort Collins, Madison and Deerfield have been instrumental in bringing our dengue and norovirus programs to late stages of clinical development,” said President of Takeda’s VBU Rajeev Venkayya.

“This consolidation will help us to achieve the efficiency and operational excellence needed to execute the Phase 3 clinical programs and set the stage for global commercialization of these vaccines.”

Zurich, Switzerland will serve as a second global hub for the vaccine unit, with regional sites in Singapore and Brazil. Takeda’s vaccine manufacturing - which takes place at facilities in Hikari, Japan; Durham, North Carolina and Singen, Germany – will not be affected by the realignment.

Related topics: Bio Developments, Pipelines, Facilities

Related news

Show more

Related products

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more